Table IV.
Association between CRM1 expression of adjacent normal tissues and clinical pathological features.
| Feature | Patients | CRM1 (IOD) | T-value | P-value |
|---|---|---|---|---|
| Gender | ||||
| Male | 83 | 172,651.86±137,014.50 | 1.073 | 0.383 |
| Female | 18 | 133,104.73±162,584.74 | ||
| Age, years | ||||
| ≤55 | 54 | 154,336.02±128,576.80 | −0.855 | 0.144 |
| >55 | 47 | 178,549.88±156,105.03 | ||
| Cirrhosis | ||||
| + | 65 | 169,193.31±140,717.66 | 0.340 | 0.394 |
| − | 36 | 159,122.89±145,626.71 | ||
| HBsAg | ||||
| + | 94 | 166,820.07±144,761.11 | 0.314 | 0.257 |
| − | 7 | 149,271.89±100,829.23 | ||
| HBeAg | ||||
| + | 19 | 217,854.03±174,268.98 | 1.802 | 0.125 |
| − | 82 | 153,497.11±131,531.72 | ||
| AFP, µg/l | ||||
| ≤400 | 86 | 160,477.47±140,133.43 | −1.086 | 0.718 |
| >400 | 14 | 204,903.30±153,643.40 | ||
| CEA, µg/l | ||||
| ≤5 | 81 | 153,332.91±136,638.43 | −0.947 | 0.355 |
| >5 | 20 | 192,052.42±145,804.10 | ||
| Diameter, cm | ||||
| ≤5 | 65 | 153,098.93±115,767.30 | 0.658 | 0.004 |
| >5 | 36 | 172,529.66±154,822.13 | ||
| Differentiation | 0.653a, 0.790b, 0.529c | |||
| Low | 44 | 168,498.02±137,486.15 | ||
| Moderate | 35 | 153,890.49±139,782.16 | ||
| High | 22 | 178,450.43±158,258.18 | ||
| AJCC stage | 0.850d, 0.690e, 0.665f | |||
| I | 91 | 167,146.51±144,340.17 | ||
| II | 5 | 179,673.43±153,475.79 | ||
| III | 4 | 137,812.58±97,291.86 | ||
Differentiation P-values:
a
Low vs. moderate
b
low vs. high
c
moderate vs. high. AJCC stage P-values:
d
I vs. II
e
I vs. III
f
II vs. III. CRM1, chromosome region maintenance 1; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; +, positive; -, negative.